$394.96 Million in Sales Expected for Amedisys Inc (AMED) This Quarter

Wall Street brokerages predict that Amedisys Inc (NASDAQ:AMED) will report $394.96 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Amedisys’ earnings, with estimates ranging from $390.40 million to $400.46 million. Amedisys reported sales of $366.30 million during the same quarter last year, which would suggest a positive year over year growth rate of 7.8%. The firm is expected to report its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Amedisys will report full year sales of $394.96 million for the current fiscal year. For the next year, analysts expect that the company will post sales of $1.63 billion per share, with estimates ranging from $1.60 billion to $1.66 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Amedisys.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Amedisys from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 7th. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Mizuho reiterated a “buy” rating and issued a $65.00 target price (up previously from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Benchmark reiterated a “hold” rating on shares of Amedisys in a research note on Thursday, November 9th. Finally, Craig Hallum restated a “buy” rating and set a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $60.64.

A number of institutional investors have recently modified their holdings of AMED. LS Investment Advisors LLC lifted its position in Amedisys by 233.1% during the fourth quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock valued at $188,000 after purchasing an additional 2,494 shares during the period. Quantitative Systematic Strategies LLC bought a new position in Amedisys in the third quarter worth approximately $205,000. NorthCoast Asset Management LLC bought a new position in Amedisys in the third quarter worth approximately $262,000. Fox Run Management L.L.C. bought a new position in Amedisys in the fourth quarter worth approximately $269,000. Finally, Janus Henderson Group PLC bought a new position in Amedisys in the second quarter worth approximately $278,000. Institutional investors own 93.73% of the company’s stock.

Amedisys (NASDAQ AMED) opened at $56.40 on Monday. The stock has a market cap of $1,914.03, a P/E ratio of 26.99, a PEG ratio of 1.18 and a beta of 0.73. Amedisys has a 52 week low of $45.60 and a 52 week high of $65.91. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.

ILLEGAL ACTIVITY NOTICE: “$394.96 Million in Sales Expected for Amedisys Inc (AMED) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/394-96-million-in-sales-expected-for-amedisys-inc-amed-this-quarter.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply